1. Search Result
Search Result
Results for "

Janus

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

1

Peptides

2

Natural
Products

6

Recombinant Proteins

3

Isotope-Labeled Compounds

9

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1122

    Fluorescent Dye Others
    Janus green B is a supravital stain. Janus green B staining reaction is oxygen dependent, and is reversibly inhibited by cyanide. Janus green B has been used for staining peripheral nerves in live insects, lymphatic vessels of rabbits and mitochondria .
    Janus green B
  • HY-N2521

    FLLL31

    STAT Apoptosis Inflammation/Immunology Cancer
    Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .
    Tetramethylcurcumin
  • HY-148785

    JAK Others
    Nimucitinib is a Janus kinase (JAK) inhibitor .
    Nimucitinib
  • HY-148791

    PG-011

    JAK Inflammation/Immunology Cancer
    Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity .
    Pumecitinib
  • HY-D1241

    Fluorescent Dye
    Janus red is a basic dye.
    Janus red
  • HY-D1131

    Fluorescent Dye
    Janus green is a basic dye.
    Janus green
  • HY-159827

    JAK Inflammation/Immunology
    Cenacitinib is a potent Janus kinase inhibitor. Cenacitinib shows anti-inflammatory activity .
    Cenacitinib
  • HY-159005

    Biochemical Assay Reagents Others
    TDTM is a photosensitizer, that promotes the generation of ROS with induction of the light. TDTM can be used for synthesis of Janus liposozyme .
    TDTM
  • HY-172432

    Tyrosinase Inflammation/Immunology
    Plodicitinib is a Janus tyrosine kinase 3/TEC family kinase inhibitor with anti-inflammatory activity .
    Plodicitinib
  • HY-153701S

    Envudeucitinib; ESK-001

    JAK Inflammation/Immunology
    Envudeucitinibum (Envudeucitinib) is a Janus kinase inhibitor, with anti-inflammatory effect .
    Envudeucitinibum
  • HY-159536

    Frevecitinib

    JAK Cancer
    Frevecitinibum (Frevecitinib) is a Janus kinase inhibitor, with anti-inflammatory effect .
    Frevecitinibum
  • HY-169184

    JAK Cancer
    GDC-9918 (compund GDC-9918) is a Janus kinase inhibitor .
    GDC-9918
  • HY-101976

    JAK Inflammation/Immunology
    JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM.
    JAK3-IN-6
  • HY-156621

    JAK Inflammation/Immunology
    Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .
    Lepzacitinib
  • HY-168984

    JAK Inflammation/Immunology Cancer
    Milpecitinib (Compound 21a) is a potent, selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory activity. Milpecitinib is promising for research of cancers and inflammatory disorders .
    Milpecitinib
  • HY-163653

    JAK Cancer
    Zemprocitinib (Compound 1) is a Janus kinase (JAK) inhibitor. The IC50 values for JAK1, JAK2 and TYK2 are 5.95, 141.3 and 119 nM, respectively .
    Zemprocitinib
  • HY-119935

    JAK Inflammation/Immunology
    JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs .
    JAK3 covalent inhibitor-1
  • HY-161259

    JAK Inflammation/Immunology
    JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1) with a IC50 value of 2.2 nM. JAK-IN-36 can be used in the study of autoimmune diseases .
    JAK-IN-36
  • HY-132849

    TD-0903

    JAK Infection Inflammation/Immunology
    Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .
    Nezulcitinib
  • HY-N15077

    Antibiotic Bacterial Infection
    11-Deacetoxywortmannin is an antibiotic found in Aspergillus janus NRRL 3807 and Penicillum funiculosum NRRL 3363. 11-Deacetoxywortmannin has a strong anti-fungal and anti-inflammatory effect, and has an anti-edema effect .
    11-Deacetoxywortmannin
  • HY-151259

    JAK Cancer
    TK4b is a Janus kinase (JAK) inhibitor with the IC50 values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively. TK4b can be used in lymphoid-derived diseases and leukemia cancer research .
    TK4b
  • HY-151258

    JAK Cancer
    TK4g is a Janus kinase (JAK) inhibitor with the IC50 values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research .
    TK4g
  • HY-156423

    Microtubule/Tubulin JAK Cancer
    Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .
    Tubulin/JAK2-IN-1
  • HY-159004

    Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    Se-DOPE is a phospholipid molecule with selenium. Se-DOPE can be used to synthesize the bifunctional Janus liposozyme. Se-DOPE promotes the production of ROS with induction of lights, scavenges the ROS with the presence of glutathione. Se-DOPE regulates redox and immune homeostasis in infected diabetic wounds .
    Se-DOPE
  • HY-112708
    Brepocitinib
    3 Publications Verification

    PF-06700841

    JAK Inflammation/Immunology
    Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively .
    Brepocitinib
  • HY-177131

    JAK Inflammation/Immunology
    Soficitinib (Compound 20) is a selective inhibitor targeting tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) with an IC50 values of 0.5 nM and 1.2 nM, respectively. Soficitinib is promising for research of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis) and inflammatory diseases .
    Soficitinib
  • HY-176347S

    Isotope-Labeled Compounds Cancer
    Alpha Feto Protein, Arg- 13C36, 15N4, Lys- 13C6, 15N2 is the 13C- and 15N-labeled Alpha Feto Protein.
    Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
  • HY-112708A
    Brepocitinib P-Tosylate
    3 Publications Verification

    PF-06700841 P-Tosylate

    JAK Inflammation/Immunology
    Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively .
    Brepocitinib P-Tosylate
  • HY-W740378

    AFN-941

    EGFR JAK Others
    1,2,3,4-Tetrahydrostaurosporine is a derivative of Staurosporine (HY-15141) and an inhibitor of mutant EGFR (IC50=74 nM for EGFRT790M). It is selective for EGFRT790M over wild-type EGFR (IC50=390 nM). It also binds to Janus kinase 3 (JAK3).
    1,2,3,4-Tetrahydro Staurosporin
  • HY-177344

    Biochemical Assay Reagents Cancer
    IAJD-97 is a single-component ionizable amphiphilic Janus dendrimer carrier targeting mRNA delivery, which self-assembles into dendrimersomes (DNPs) via pH-responsive mechanisms to efficiently encapsulate and protect mRNA, while facilitating cellular uptake and endosomal escape through ionizable amine groups. IAJD-97 is promising for research of cancers .
    IAJD-97
  • HY-149257

    JAK STAT Cancer
    HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions .
    HAT-SIL-TG-1&AT
  • HY-19569A

    ABT-494 tartrate tetrahydrate

    JAK Inflammation/Immunology
    Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .
    Upadacitinib tartrate tetrahydrate
  • HY-19569
    Upadacitinib
    Maximum Cited Publications
    22 Publications Verification

    ABT-494

    JAK Inflammation/Immunology
    Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .
    Upadacitinib
  • HY-174665

    mRNA Cancer
    Human IFNAR2 mRNA encodes the human interferon alpha and beta receptor subunit 2 (IFNAR2) protein, a protein that belongs to the type II cytokine receptor family. IFNAR2 is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2.
    Human IFNAR2 mRNA
  • HY-161618

    JAK EGFR PI3K IGF-1R GSK-3 Inflammation/Immunology Endocrinology
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg) .
    MJ04
  • HY-P10373

    JAK Infection
    pJAK2(1001-1013) is a SOCS1/3 antagonist. pJAK2(1001–1013) plays a positive role in antiviral immune response by inhibiting the negative regulatory effect of SOCS proteins and enhancing the JAK/STAT signaling pathway
    pJAK2(1001–1013)
  • HY-19569R
    Upadacitinib (Standard)
    1 Publications Verification

    ABT-494 (Standard)

    Reference Standards JAK Inflammation/Immunology
    Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .
    Upadacitinib (Standard)
  • HY-125019

    JAK STAT Inflammation/Immunology
    iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .
    iJak-381
  • HY-18200A

    E5555 hydrochloride; ER-172594-00 hydrochloride

    Protease Activated Receptor (PAR) JAK Apoptosis Cardiovascular Disease Cancer
    Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC50 of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC50=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease .
    Atopaxar hydrochloride
  • HY-W727879
    Upadacitinib-15N,d2
    1 Publications Verification

    ABT-494-15N,d2

    Isotope-Labeled Compounds Others
    Upadacitinib- 15N,d2 (ABT-494- 15N,d2) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- 15N,d2 (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib- 15N,d2 (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- 15N,d2 (ABT-494) can be used for several autoimmune disorders research .
    Upadacitinib-15N,d2
  • HY-15163A

    FLT3 JAK CDK Cancer
    Zotiraciclib hydrochloride is a novel small molecule multi-target enzyme inhibitor with activity in inhibiting tumor growth. Zotiraciclib hydrochloride exerts its anti-tumor effect by reducing the level of Myc through inhibiting cyclin-dependent kinase 9 (CDK9). Zotiraciclib hydrochloride may be useful for inhibiting cancers that cross the blood-brain barrier. The high protein level of MCL-1 of Zotiraciclib hydrochloride is associated with survival, suggesting that it may serve as a prognostic factor and inhibitory target in further studies .
    Zotiraciclib hydrochloride
  • HY-15163
    Zotiraciclib
    1 Publications Verification

    TG02; SB1317

    JAK CDK FLT3 Cancer
    Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .
    Zotiraciclib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: